Zusammenfassung
Obgleich Erythromycin seit mehr als 25 Jahren in der Therapie benutzt wird, fehlt bisher eine zusammenfassende Darstellung seiner Gewebegängigkeit. In der vorliegenden Übersicht werden neben den bei verschiedenen Derivaten in Dosis- und Zeitabhängigkeit nach oraler Gabe erreichbaren Serumspiegelspitzen die Erythromycin-Gewebespiegel ausführlich dokumentiert. Die Höhe der Spiegel im Gewebe übertrifft häufig die entsprechenden MHK-Werte Erythromycin-empfindlicher Erreger um ein Mehrfaches. Das Zentralnervensystem wird jedoch von Erythromycin nicht, bzw. nur in sehr geringem und nicht vorhersehbarem Ausmaß erreicht. Ähnliches gilt für die Plazenta-Passage des Erythromycins. Die Gewebespiegel bestätigen in Hinblick auf die MHK-Werte des Erregerspektrums die klinischen Erfahrungen für eine Therapie mit Erythromycin bei Infektionen des HNO-Bereiches und der Atemwege, sowie — mit gewissen Einschränkungen — bei Chlamydien-Urethritis.
Summary
Tissue Penetration of Erythromycin. A Comparative Review. Although erythromycin has been used in therapy for more than 25 years, until now there has been no paper summarizing the data on tissue penetration. The present review documents in detail dose- and time-related peak serum levels of erythromycin derivatives after oral administration, in addition to the erythromycin tissue levels. The erythromycin tissue levels often manifoldly exceed the corresponding MIC values of pathogens sensitive to erythromycin. However, erythromycin does not penetrate the central nervous system, or only penetrates in small, incalculable amounts. The same applies for the placental passage of erythromycin. The tissue levels confirm, with respect to the MIC values of the pathogen spectrum, clinical experience with erythromycin in the treatment of ear, nose and throat infections, respiratory tract infections and, with some limitationsChlamydia urethritis.
Article PDF
Avoid common mistakes on your manuscript.
Literatur
Lacey, R. W. A new look at erythromycin. Postgrad. Med. J. 53 (1977) 195–200.
Knothe, H. A review of the medical considerations of the use of tylosin and other macrolide antibiotics as additives in animal feeds. Infection 5 (1977) 183–187.
Sherlock, S. Hepatic reactions to therapeutic agents. Ann. Rev. Pharmacol. 5 (1965) 429–446.
Dette, G. A.: Taux de concentration sérique et tissulaire de l'Erythromycine. Gaz. Méd. (1979) im Druck.
Griffith, R. S., Stephens, V. C., Wolfe, R. N., Boniece, W. S., Lee, C. C. Preliminary studies on propionyl erythromycin. Antibiot. Med. Clin. Ther. 5 (1958) 609–613.
Josselyn, L. E., Endicott, C., Sylvester, J. C. Absorption of erythromycin. III. Various pharmaceutical forms. Antibiot. Ann. 1954–1955 (1955) 279–282.
Gavrilina, T. N., Lagert, I. K. Эритромицин в лечении хроническин пневмонип. Ter. Arkh. 36 (1964) 40–44.
Perry, D. M., Hall, G. A., Kirby, W. M. M. Triacetyloleandomycin and erythromycin: a comparison of in vitro activity and of blood levels obtained after oral administration. Antibiot. Med. Clin. Ther. 6 (1959) 347–352.
Griffith, R. S., Black, H. R. A comparison of blood levels after oral administration of erythromycin and erythromycin estolate. Antibiot. Chemother. 12 (1962) 398–403.
Griffith, R. S. Laboratory and clinical studies with erythromycin propionate. Antibiot. Ann. 1958–1959 (1959) 364–374.
Josselyn, L. E., Sylvester, J. C. Absorption of erythromycin. Antibiot. Chemother. 3 (1953) 63–66.
Grigsby, M. E., Johnson, J. B., Simmons, G. W. Some laboratory and clinical experiences with erythromycin. Antibiot. Chemother. 3 (1953) 1029–1034.
Kirby, W. M. M., Maple, F. M., O'Leary, B. Erythromycin serum concentrations following administration in acid-resistant tablets. Antibiot. Chemother. 3 (1953) 473–477.
Männistö, P., Tuomisto, J., Räsänen, R. Absorption of erythromycin. A cross-over study in healthy volunteers. Arzneim. Forsch. 25 (1975) 1828–1831.
Smith, J. W., Dyke, R. W., Griffith, R. S. Absorption following oral administration of erythromycin. J. Am. Med. Ass. 151 (1953) 808–810.
Heilman, F. R., Herrell, W. E., Wellman, W. E., Geraci, J. E. Some laboratory and clinical observations on a new antibiotic, erythromycin (Ilotycin). Proc. Staff Meet. Mayo Clin. 27 (1952) 285–304.
Parsons, R. L., Paddock, M., Hossack, A. Particular aspects of the pharmacokinetics of erythromycin. Infection 5 Suppl. 1 (1977) 23–28.
Coyne, T. C., Shum, S., Chun, A. H. C., Jeansonne, L., Shirkey, H. C.: Bioavilability of erythromycin ethylsuccinate in pediatric patients. J. Clin. Pharmacol. (1978) 194–202.
Vanhoof, R., Clumeck, N., Demol, P., Vanderlinden, M. P., Butzler, J. P., Yourassowsky, E. Clinical and pharmacological evaluation of erythromycin ethylsuccinate in patients with chronic bronchitis. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 34–37.
Simon, C., Clasen, I. Sputum levels of erythromycin after single and repeated oral administration in adult patients with bronchitis. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 19–22.
Hirsch, H. A., Finland, M. Effect of food on the absorption of erythromycin propionate, erythromycin stearate, and triacetyloleandomycin. Am. J. Med. Sci. 237 (1959) 693–709.
Hall, G. A., Roberts, C. E., Perry, D. M., Kirby, W. M. M. Erythromycin stearate and propionyl erythromycin: a comparison of blood levels obtained after oral administration. Antibiot. Med. Clin. Ther. 7 (1960) 231–234.
Hirsch, H. A., Kunin, C. M., Finland, M. Antibacterial activity of serum of normal men after oral doses of erythromycin propionate and triacetyloleandomycin. N. Engl. J. Med. 260 (1959) 408–412.
Perry, D. M., Hall, G. A., Kirby, W. M. M. Clinical and laboratory studies of erythromycin propionate. Antibiot. Ann. 1958–1959 (1959) 375–381.
Griffith, R. S., Black, H. R. Comparison of the blood levels obtained after single and multiple doses of erythromycin estolate and erythromycin stearate. Am. J. Med. Sci. 247 (1964) 69–74.
Bell, S. M.: A comparison of absorption after oral administration of erythromycin estolate and erythromycin stearate. Med. J. Austr. (1971) 1280–1283.
Malmborg, A. S. Absorption of erythromycin stearate after oral administration. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 15–18.
Sylvester, J. C., Josselyn, L. E. Absorption of erythromycin. II. Erythromycin stearate. Antibiot. Chemother. 3 (1953) 930–932.
Triggs, E. J., Ashley, J. J.: Oral administration of erythromycin stearate: effect of dosage form on plasma levels. Med. J. Austr. (1978) 121–123.
Wiegand, R. G., Chun, A. H. C. Serum protein binding of erythromycin and erythromycin 2′-propionate ester. J. Pharm. Sci. 61 (1972) 425–428.
Lopez-Belio, M., Takimura, Y., Fornatto, E. J., Holinger, P H. Erythromycin in the bronchial tree after oral, intravenous, and aerosol administration. Antibiot. Ann. 1956–1957 (1957) 152–158.
Fraschini, F., Copponi, V., Dubini, F., Scarpazza, G. Concentration of erythromycin and ampicillin in bronchial secretions of patients with chronic respiratory infections. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 23–27.
Eliasson, R., Malmborg, A. S., Dornbusch, K., Kvist, U. Secretion of erythromycin into human semen: methodological, experimental and clinical aspects. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 31–33.
Lopez-Belio, M., Takimura, Y. Intrapleural, intravenous, and oral administration of erythromycin. Antibiot. Ann. 1954–1955 (1955) 295–311.
Spitzy, K. H., Hitzenberger, G. The distribution volume of some antibiotics. Antibiot. Ann. 1957–1958 (1958) 996–1003.
Welling, P. G., Craig, W. A. Pharmacokinetics of intravenous erythromycin. J. Pharmaceut. Sci. 67 (1978) 1057–1059.
Lee, C. C., Anderson, R. C., Chen, K. K. Tissue distribution of erythromycin in rats. Antibiot. Chemother. 3 (1953) 920–924.
Akashi, T., Kaneko, T., Sasa, T., Matsui, H. Chemical determination and clinical application of antibiotics of the erythromycin and leucomycin group. Abstr. Jap. Med. 1 (1960) 36.
Benazet, F., Dubost, M. Apparent paradox of antimicrobial activity of spiramycin. Antibiot. Ann. 1958–1959 (1959) 211–220.
Anderson, R. C., Lee, C. C., Worth, H. M., Harris, P. N. Pharmacology and toxicology of propionyl erythromycin ester lauryl sulfate. J. Am. Pharm. Ass. 48 (1959) 623–628.
Koroleva, V. G., Vasilev, V. K. сравнительная оценка всасывания и распределения различных препаратов Эритромицина при парентеральном применении. Antibiotiki 13 (1968) 431–434.
Lee, C. C., Anderson, R. C., Bird, H. L., Chen, K. K. Reabsorption of erythromycin and a microbiologically active metabolite in the bile of dogs and rats. Antibiot. Ann. 1953–1954 (1954) 493–495.
Brusch, J. L., Barza, M., Brown, R. B., Bergeron, M. G., Weinstein, L. Comparative pharmacokinetics of thirteen antibiotics in dogs. With especial reference to concentrations in liver, kidney, bile and urine. Infection 4 Suppl. 2 (1976) 82–90.
Uberti, E. Ricerche sulla eliminazione della eritromicina nelle vie biliari patologiche dell'uomo. Giornale Ital. Chemother. 3 (1956) 36–41.
Lee, C. C., Anderson, R. C., Chen, K. K. Site of absorption of erythromycin in rats. Antibiot. Chemother. 4 (1954) 926–930.
Chabbert, Y., Boyer, F., Saviard, M., Boulingre, H., Hervé, J. Determination de l'action bactéricide in vivo des antibiotiques dans la staphylococcie rénale de la souris. Ann. Inst. Pasteur 92 (1957) 760–777.
Griffith, R. S., Johnstone, D. M., Smith, J. W. The distribution and excretion of erythromycin following intravenous injection. Antibiot. Ann. 1953–1954 (1954) 496–499.
Winningham, D. G., Nemoy, N. J., Stamey, T. A. Diffusion of antibiotics from plasma into prostatic fluid. Nature (London) 219 (1968) 139–143.
Madsen, P. O., Baumueller, A., Hoyme, U. Experimental models for determination of antimicrobials in prostatic tissue, interstitial fluid and secretion. Scand. J. Infect. Dis. Suppl. 14 (1978) 145–150.
Documenta Geigy. Wissenschaftliche Tabellen. J. R. Geigy, Basel, 1968, p. 678.
Armstrong, J. R., Cook, F. E., Robison, J. R. Concentration of antibiotic and chemotherapeutic agents in the ejaculum. J. Urol. 100 (1968) 72–76.
Dette, G. A., Knothe, H., Schäfer, V., Maassen, W., Wadoud, E. The effect of bromhexine on erythromycin concentrations in serum and lung tissue. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 38–41.
Zinnemann, K. Haemophilus influenzae and its pathogenicity. Curr. Top. Microbiol. Immunol. 33 (1960) 307–368.
Neaverson, M. A. Intravenous administration of erythromycin: serum, sputum and urine levels. Curr. Med. Res. Opinion 4 (1976) 359–364.
Gould, J. C. The action of erythromycin and penicillin on the bacterial flora in tonsil tissue. Chemotherapy 1 (1976) 319–325.
Georgiew, S., Gröger, H., Flood, M. K. Comparative serum and tissular tissue concentration of two macrolides. J. Antimicrob. Chemother. 4 (1978) 472–473.
Sundberg, L., Eden, T., Ernstson, S. Penetration of erythromycin into middle ear secretions: a preliminary report. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 28–30.
Bass, J. W., Steele, R. W., Wiebe, R. A., Dierdorff, E. P. Erythromycin concentrations in middle ear exudates. Pediatrics 48 (1971) 417–422.
Kaminszczick, J., Galan, H.: Interés del estudio de los niveles tisulares de antibióticos en sinusopatías. Sem. Med. (Buenos Aires) (1971) 1280–1285.
Kalm, O., Kamme, C., Bergström, B., Löfkvist, T., Norman, O. Erythromycin stearate in acute maxillary sinusitis. Scand. J. Infect. Dis. 7 (1975) 209–217.
Lamberg, H. P. Clincal significance of tissue penetration of antibiotics in the respiratory tract. Scand. J. Infect. Dis. Suppl. 14 (1978) 262–266.
Gross, A., Uotinen, K. G. Elimination of antibiotics in submaxillary and parotid saliva of unanesthetized dogs. Pharmacol. Therapeut. Dentistry 1 (1970) 46–55.
LoRusso, D., Tomasetti, L. Ricerche sull'eliminazione di eritromicina da parte delle diverse ghiandole salivari. Boll Mal. Orecch. 83 (1965) 606–617.
Grady, J. E., Stern, K. F.: Penetration of lincomycin into bone. Antimicrob. Agents Chemother. (1965) 201–205.
Anderson, R. C., Harris, P. N., Chen, K. K. The toxicity and distribution of “Ilotycin”. J. Am. Pharm. Ass. 41 (1952) 555–559.
Mosijchuk, N. M. проницаемость гематоэнцефалическ ого Барьера для антиБиот иков у Больных гнойным менингитом. Zh. Nevropat. Psikhat. 68 (1961) 338–342.
Lee, C. C., Froman, R. Passage of erythromycin into the aqueous humor. Antibiot. Chemother. 11 (1961) 107–109.
Furgiuele, F. P. New antibiotics: their intraocular penetration. Part II. Amer. J. Ophthal. 58 (1964) 443–447.
Moya, F.: Mechanisms of drug transfer across the placenta with particular reference to chemotherapeutic agents. Antimicrob. Agents Chemother. (1965) 1051–1057.
Kiefer, L., Rubin, A., McCoy, J. B., Foltz, E. L. The placental transfer of erythromycin. Amer. J. Obstet. Gynecol. 69 (1955) 174–177.
v. Kobyletzki, D., Strauch, D. Experimentelle Untersuchungen zur Frage der diaplazentaren Passage und der Ausscheidung mit der Muttermilch von Erythromycin-Estolat (PELS). Z. Geburtsh. Gynäk. 162 (1964) 36–45.
v. Kobyletzki, D. Über die Beinflussung des Neugeborenen durch die Verabfolgung von Medikamenten unter der Geburt. Geburtsh. Frauenheilk. 25 (1965) 351–356.
Philipson, A., Sabath, L. D., Charles, D. Transplacental passage of erythromycin and clindamycin. N. Engl. J. Med. 288 (1973) 1219–1221.
South, M. A., Short, D. H., Knox, J. M. Failure of erythromycin estolate therapy in utero syphilis. J. Am. Med. Ass. 190 (1964) 182–183.
Rasmussen, F. Mammary excretion of benzylpenicillin, erythromycin, and penethamate hydroiodide. Acta Pharmacol. Toxicol. 16 (1959) 194–200.
Knowles, J. A. Excretion of drugs in milk — a review. J. Pediatr. 66 (1965) 1068–1082.
v. Kobyletzki, D. Eigene Untersuchungen über die Pharmakokinetik während der Peripartalzeit und Stillzeit. Med. Welt 19 (1968) 2010–2019.
Documenta Geigy. Wissenschaftliche Tabletten. J. R. Geigy, Basel, 1968, p. 684.
Kislak, J. W., Razavi, L. M. B., Daly, A. K., Finland, M. Susceptibility of pneumococci to nine antibiotics. Am. J. Med. Sci. 250 (1965) 261–268.
Finland, M., Garner, C., Wilcox, C., Sabath, L. D.: Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents. Antimicrob. Agents Chemother. (1976) 274–287.
Cleary, T. J., Villa, S., Sands, L., Hoffman, T. A. Comparative in vitro activity of josamycin, erythromycin, clindamycin and penicillin. Curr. Ther. Res. 23 (1978) 351–357.
Marks, M. I. In vitro activity of clindamycin and other antimicrobials against gram-positive bacteria and Haemophilus influenzae. CMA J. 112 (1975) 170–173.
Garrod, L. P., Lambert, H. P., O'Grady, F.: Antibiotic and Chemotherapy. E. & S. Livingstone, Edigburgh, 1973, p. 168.
Griffith, R. S., Black, H. R. Erythromycin. Med. Clin. N. Amer. 54 (1970) 1199–1215.
Dixon, J. M. S., Lipinski, A. E., Graham, M. E. P. Detection and prevalence of pneumococci with increased resistance to penicillin. CMA J. 117 (1977) 1159–1161.
Romansky, M. J., Nasou, J. P., Davis, D. S., Ritts, R. E. Clinical spectrum of erythromycin as evaluated in 260 patients. J. Am. Ass. 164 (1957) 1197–1204.
Jones, W., Feldman, H., Finland, M. Susceptibility of hemolytic streptococci, other than those of group D, to eleven antibiotics in vitro. Am. J. Clin. Path. 27 (1957) 159–169.
Yoshioka, H., Rudoy, R., Riley, H. D., Yoshida, K. Antibiotic susceptibilities of 120 strains ofStaphylocossus aureus isolated from patients at a children's hospital. Decline of hospital staphylococci as compared with staphylococci in outpatients. A reversal. Clin. Pediatrics 15 (1976) 428–431.
Kim, H. B., Okumoto, M., Smolin, G. Quantitative antibiotic sensitivity determinations ofStaphylococcus aureus isolated from eye cultures. Arch. Ophthalmol. 95 (1977) 1065–1067.
Hassam, Z., Shaw, E. J., Shooter, R. A., Caro, D. B.: Changes in antibiotic sensitivity in strains ofStaphylococcus aureus, 1952–78. Br. Med. J. (1978) 536–537.
Wallmark, G., Finland, M. Phage types and antibiotic susceptibility of pathogenic staphylococci. J. Am. Med. Ass. 175 (1961) 886–897.
Waisbren, B. A., Strelitzer, C. L. A five year study of the antibiotic sensitivities and cross resistances of staphylococci in a general hospital. Antibiot. Ann. 1957–1958 (1958) 350–364.
Haight, T. H., Finland, M. The antibacterial action of erythromycin. Proc. Soc. Exp. Biol. Med. 81 (1952) 175–183.
Castete, M., Mora, M.: Sensibilité aux antibiotiques deCorynebacterium diphtheriae. Presse Méd. (1974) 962.
Simon, C., Bontemps, M., Wiese, K., Schewior-Roland, R. Zur Ampicillin-Therapie des Keuchhustens. Dtsch. Med. Wschr. 94 (1969) 2435–2437.
Bass, J. W., Crast, F. W., Kotheimer, J. B., Mitchell, J. A. Susceptibility ofBordetella pertussis to nine antimicrobial agents. Amer. J. Dis. Child 117 (1969) 276–280.
Jao, R. L., Finland, M. Susceptibility ofMycoplasma pneumoniae to 21 antibiotics in vitro. Amer. J. Med. Sci. 253 (1967) 639–650.
Williams, J. D., Andrews, J.: Sensitivity ofHaemophilus influenzae to antibiotics. Brit. Med. J. (1974) 134–137.
Khan, W., Ross, S., Zaremba, E. A.: Comparative inhibition ofHaemophilus influenzae by eight antibiotics. Antimicrob. Agents Chemother. (1966) 393–396.
Gordon, R. C., Thompson, T. R., Stevens, L. I., Carlson, W. H.: In vitro susceptibility ofHaemophilus influenzae to eight antibiotics. Antimicrob. Agents Chemother. (1974) 114–115.
McBride, V. E., Dowling, H. F., Mellody, M.: Comparison of tube and plate methods for testing combinations of antibiotics againstHaemophilus influenzae. Antimicrob. Agents Chemother. (1965) 267–272.
Gould, J. C. Erythromycin in respiratory tract infection. Scot. Med. J. 22 (1977) 355–359.
McLinn, S. E., Nelson, J. D., Haltalin, K. C. Antimicrobial susceptibility ofHaemophilus influenzae. Pediatrics 45 (1970) 827–838.
Blenk, H., Blenk, B., Hofstetter, A., Schmiedt, W. Activity of erythromycin againstChlamydiae in vitro and in vivo, and its use in genitalChlamydia infections. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 61–68.
Werner, H. Zur In-vitro-Aktivität von Erythromycin und Clindamycin/Lincomycin gegenüber Anaerobiern. Infection 5 Suppl. 1 (1977) 58–65.
Werner, H., Lang, N., Krasemann, C., Tolkmitt, G., Feddern, R. Epidemiology of anaerobic infections of the female genitourinary tract, and preliminary results of therapy with erythromycin. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 52–55.
Author information
Authors and Affiliations
Additional information
Prof.H. Knothe zum 60. Geburtstag.
Rights and permissions
About this article
Cite this article
Dette, G.A. Vergleich der Gewebegängigkeit von Erythromycin. Infection 7, 129–145 (1979). https://doi.org/10.1007/BF01641314
Issue Date:
DOI: https://doi.org/10.1007/BF01641314